Previous Close | 0.0925 |
Open | 0.0839 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 0.0839 - 0.0955 |
52 Week Range | 0.0630 - 0.1600 |
Volume | |
Avg. Volume | 49,740 |
Market Cap | 12.223M |
Beta (5Y Monthly) | 0.54 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.3300 |
Earnings Date | Jun 12, 2024 - Jun 17, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
RIV Capital Inc. ("RIV Capital" or the "Company") (CSE: RIV) (OTC: CNPOF), an acquisition and investment firm with a focus on building a leading multi-state platform with one of the strongest portfolios of brands in key strategic U.S. markets, today applauds reports that the U.S. Drug Enforcement Agency proposes to reschedule cannabis under the Controlled Substance Act (the "CSA") from Schedule I to a Schedule III substance. A rescheduling of cannabis under the CSA is expected to lead to the rem
RIV Capital Inc. ("RIV Capital" or the "Company") (CSE: RIV) (OTC: CNPOF), an acquisition and investment firm with a focus on building a leading multistate platform with one of the strongest portfolios of brands in key strategic U.S. markets, today released its financial results for the three months and nine-month transition period ended December 31, 2023. As previously announced, due to a change in the Company's fiscal year end from March 31st to December 31st, the Company's most recent fiscal
RIV Capital Inc. ("RIV Capital" or the "Company") (CSE: RIV) (OTC: CNPOF), an acquisition and investment firm with a focus on building a leading multistate platform with one of the strongest portfolios of brands in key strategic U.S. markets, will report its financial results for the three months and nine-month transition period ended December 31, 2023, after markets close on Monday, April 29, 2024. As previously announced, due to a change in the Company's fiscal year end from March 31st to Dece